Excellent overview in The Washington Post on the systemic impact of sustained hypertension — from LVH to CKD and cognitive decline.
Kudos to Drs. @drwanpen.bsky.social , John B, and @jordybc.bsky.social for evidence base insight.
🔗 www.washingtonpost.com/wellness/202...
#Hypertension #Cardiology
Think I just had a pt with olmesartan enteropathy
Yall seeing this? I’ve mostly moved away to tel, irb but have a fair number of legacy pts
#medsky #cardiosky #nephsky
🧠 Dr. Vaidya’s @anandvaidya17.bsky.social
practical approach to primary aldo, distilled into one clean, clinic-ready infographic:
This is high-yield, no-fluff, practice-changing stuff.
New! 🎙️🩺🎧 #515 Primary Aldosteronism, A Deep Dive: Easy on the Salt! 🧂⬇️
Hypertension is everywhere and primary aldosteronism is a common (and often missed 👀) cause. Join us with @anandvaidya17.bsky.social of Brigham and Women’s Hospital
www.youtube.com/watch?v=mqpl...
23.02.2026 19:58 — 👍 2 🔁 2 💬 0 📌 0
UKKA BP in dialysis visual abstract
Very practical UK Kidney Association guidelines for management of BP in Dialysis
www.kireports.org/article/S246...
KI Reports
figure 1
sweet
A @asnpublications.bsky.social perspective argues we need a Spironolactone versus nsMRA head:head trial!
journals.lww.com/jasn/pages/a...
Bring it on!
#NephSky #SpiroStans rejoice
Excited to share our research letter published today in JAMA on the new Apple Watch Hypertension Notification Feature! jamanetwork.com/journals/jam...
1/n
Thank you @asnpublications.bsky.social for posting our paper on the transformation of venous to arterial blood gas. To facilitate calculations, I developed an App “Venous to Arterial Blood Gas” available for free (apps.apple.com/us/app/venou...)
@nu-nephrology.bsky.social @feinberg.northwestern.edu
For example, my institution's lab historically reported renin/aldo with these reference ranges. Cases of overt PA could be interpreted as normal. But results are now reported with guidance on interpretation with the relevant cutoffs from our lab's assays.
23.01.2026 13:30 — 👍 4 🔁 1 💬 1 📌 0
I think there could be more clarity in how many labs report results. i.e what threshold should be considered a suppressed renin, positive screen, etc. The variety of different assays/units remains a major source of confusion. Most clinicians won't be aware of Table 5 from the Endo society guideline
23.01.2026 13:22 — 👍 5 🔁 2 💬 2 📌 0I'm in favor of doing the initial screen in non-optimal setting. Remove barriers to testing. The most overt cases will still be identified. In borderline cases if clinical suspicion is still high, can repeat under more standardized conditions (including considering medication effects).
23.01.2026 13:13 — 👍 1 🔁 0 💬 1 📌 0
https://www.endocrine.org/clinical-practice-guidelines/primary-aldosteronism-2
As guidelines rec more Aldo/renin testing in htn, wondering whats labs role to ensure/capture details on relevant factors (timing, Na restriction, meds, KP)? Should labs rec pts test in more standardized conditions, log key details or just do it-clinicians duty to sort out? @askrenal.bsky.social
22.01.2026 13:37 — 👍 4 🔁 2 💬 2 📌 0
Excited to share our thoughts on the Apple Watch Hypertension alert!
@jordybc.bsky.social @deanpicone.bsky.social @alta-schutte.bsky.social
Apple Watch for Hypertension Screening | Hypertension www.ahajournals.org/doi/10.1161/...
Cuffless BP review with @farahwehbe92.bsky.social - incoming HT fellow in Ottawa, with tables, and details of technology, devices and ongoing trials
pubmed.ncbi.nlm.nih.gov/41460057/
thanks to @profdg.bsky.social for the invite!
Dan Batlle & I wrote about testing for primary aldosteronism, bringing a critical lens to the usual approach
www.ahajournals.org/doi/full/10....
We have so much evidence demonstrating the real clinical impact of renin (predicting response to MRAs in PATHWAY-2, increased CV risk when renin remains suppressed, etc). I would hope AngII testing could be incorporated into trials to build a dataset for comparison.
23.12.2025 02:16 — 👍 0 🔁 1 💬 1 📌 0Thought-provoking read! I wonder if this should be a more common measurement in clinical trials (nsMRAs, ASIs, etc) since the studies so far have involved small numbers of patients. Without more concrete data showing the clinical utility it is hard to justify muddying the waters more.
23.12.2025 02:10 — 👍 1 🔁 0 💬 1 📌 0
🚨 Fresh Hypertension Guidelines Alert 🚨
Don’t get caught treating high blood pressure like it’s 2024 👀
In Episode #509, West Philly doc Dr. Jordy Cohen @jordybc.bsky.social
keeps our hypertension management fresh with a clear walk-through of the new HTN guidelines & more!
www.thecurbsiders.com
AHA Scientific Statement on Single-Pill Combination Therapy
www.ahajournals.org/doi/10.1161/... #Nephsky
If you are interested in hypertension training and research, check out our hypertension fellowship.
research.bidmc.org/medicine-gme...
Happy to contribute to this important statement
@ahascience.bsky.social on cuffless devices led by @jordybc.bsky.social !
Cuffless Devices for the Measurement of Blood Pressure: A Scientific Statement From the American Heart Association | Hypertension ahajournals.org/doi/10.1161/...
"Older and Black participants had higher aldo-to-renin ratio...and women had higher aldo levels than men across the lifespan. With newly expanded indications for PA testing, a greater appreciation of the influence of demographic characteristics will be required." #nephsky
tinyurl.com/yc8ryxmu
VA of SPARK trial
Our take on the baxdrostat PA trial in @asnpublications.bsky.social #KidneyNews
www.kidneynews.org/view/journal... with @nephroseeker.medsky.social and @dramiliflores.bsky.social !
Thanks to Sam Kant and @kdjhaveri.bsky.social for the invite!!
🆕 #NephJCshort by @brianrifkin.bsky.social
RETREAT-FRAIL- pragmatic RCT: is less BP medication worse in octogenarians?
www.nephjc.com/news/hyperte...
My first month of trying to prescribe fish oil at the dialysis unit has been a total failure
Pharmacies arn’t filling scripts and patients can’t find OTC matches to dose prescribed in PISCES
Anyone having success on the high seas?
To Treat or Not to Treat? Watchful Waiting or Oral Antihypertensives for Asymptomatic Inpatient Hypertension
#nephsky #nephrology
www.nejm.org/doi/full/10....
Ahead of #KidneyWk25, we are recruiting a hypertension fellow to the Stanford Hypertension Center for July 2026. Please come find me at ASN.
med.stanford.edu/nephrology/e...
Samir Parikh gives an update on lupus nephritis. #KidneyWk Looking for rapid reduction of proteinuria? Voclosporin is faster, but belimumab showed similar separation from placebo, it just takes longer due to mechanism of action.
05.11.2025 15:38 — 👍 8 🔁 4 💬 2 📌 0
A visual representation of the BaxHTN phase 3 trial, which evaluated baxdrostat, a highly selective, potent aldosterone synthase inhibitor, in patients with hard-to-control hypertension.
BaxHTN phase 3 trial: Aldosterone dysregulation is considered a key driver of hard-to-control hypertension. Research findings on baxdrostat, a highly selective, potent aldosterone synthase inhibitor, in hard-to-control hypertension are summarized in a new Quick Take video. nej.md/3KCsQGJ
15.10.2025 19:02 — 👍 12 🔁 5 💬 0 📌 1